Eloralintide

• Slow escalation to 9 mgrecommended

  Reproduces the 3/6/9 mg arm of NCT06230523. Investigational; Monday dosing.

• Faster escalation to 9 mg

  Reproduces the 6/9 mg arm of NCT06230523. This arm had the highest reported nausea and fatigue rates among the escalation arms.

• Trial arm 3/6/9 mg: 3 mg once weekly for 4 weeks, 6 mg for 4 weeks, then 9 mg for 40 weeks (48 weeks total).
• Trial arm 6/9 mg: 6 mg once weekly for 20 weeks, then 9 mg for 28 weeks (48 weeks total).
• Other trial arms were fixed 1, 3, 6 or 9 mg once weekly for 48 weeks.

Route: Subcutaneous, once weekly (trial).

Timing: Same day each week; the sources give no time-of-day guidance.

• No reconstitution figure exists: the trial product is a Lilly clinical-supply formulation, not a research vial. The water in the protocols is arithmetic for a readable draw, not a sourced instruction.

No reliable figure found in the sources; ask your prescriber or supplier.

No off-cycle in the trial (continuous 48 weeks).

Why:

• Trial arms were continuous; no sourced washout.

• Never draw into the same syringe as another compound; use separate syringes and distinct injection sites.

Investigational; not approved anywhere. Any vial sold outside a trial is unapproved and unverified.

Common side effects:

• Most common in the phase 2 trial: nausea (up to 64% at 6 mg, 33% at 9 mg vs 14% placebo) and fatigue (up to 46% in the 6/9 mg arm), mostly dose-related (PubMed abstract).
• Per Outliyr: constipation 24%, vomiting 11% and alopecia 11% at 9 mg; slow heart rate in 11% of the 6 mg arm (unexplained).

Stop and call your prescriber if:

• Severe or persistent vomiting, or signs of dehydration
• Severe upper abdominal pain radiating to the back
• Resting heart rate well below normal, or dizziness on standing
• Shakiness, sweating or confusion, especially with insulin or a sulfonylurea

What sources report this compound changes, or say to check. A record of the evidence, not targets or advice.

• Body weightReported changeHuman trial

  Mean change at 48 weeks: -9% (1 mg) to -20% (9 mg) vs -0.4% placebo (phase 2, 263 adults with obesity or overweight)

  PubMed: phase 2 obesity trial (Lancet 2025)

• ClinicalTrials.gov NCT06230523: phase 2 arms and dosing (LY3841136)
• PubMed: phase 2 obesity trial (Lancet 2025)
• Outliyr eloralintide report (escalation, adverse events, status)